Use este identificador para citar ou linkar para este item: http://www.alice.cnptia.embrapa.br/alice/handle/doc/9091
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorHERNANDEZ FERNANDEZ, J.
dc.contributor.authorNESHICH, G.
dc.contributor.authorCAMARGO, A. C. M.
dc.date.accessioned2018-01-26T23:36:28Z-
dc.date.available2018-01-26T23:36:28Z-
dc.date.created2005-08-04
dc.date.issued2004
dc.identifier.citationGenetics and Molecular Research, v. 3, n. 4, p. 554-563, 2004.
dc.identifier.urihttp://www.alice.cnptia.embrapa.br/alice/handle/doc/9091-
dc.descriptionAngiotensin I-converting enzyme (ACE) is a dipeptidyl-carboxypeptidase expressed in endothelial, epithelial and neuroepithelial cells. It is composed of two domains, known as N- and C-domains, and it is primarily involved in blood pressure regulation. Although the physiological functions of ACE are not limited to its cardiovascular role, it has been an attractive target for drug design due to its critical role in cardiovascular and renal disease. We examined natural structures based on bradykinin-potentiating peptides (BPPs) extracted from Bothrops jararaca venom for ACE inhibition. Modeling, docking and molecular dynamics were used to study the conserved residues in the S2´, S1´ and S1 positions that allow enzyme-substrate/inhibitor contacts. These positions are conserved in other oligopeptidases, and they form tight and non-specific contacts with lisinopril, enalapril and BPP9a inhibitors. The only specific inhibitor for human somatic ACE (sACE) was BPP9a, which is instable in the N-sACE-BPP9a complex due to repulsive electrostatic interactions between Arg P4-Arg 412 residues. Specificity for the C-terminal domain in human sACE inhibition was confirmed by electrostatic interaction with the Asp 1008 residue. Peptide-like BPP structures, naturally developed by snakes across millions of years of evolution, appear to be good candidates for the development of domain-selective ACE inhibitors with high stability and improved pharmacological profiles.
dc.language.isoengeng
dc.rightsopenAccesseng
dc.subjectHipertensão
dc.subjectModelagem
dc.subjectDinâmica molecular
dc.subjectModeling
dc.titleUsing bradykinin-potentiating peptide structures to develop new antihypertensive drugs.
dc.typeArtigo de periódico
dc.date.updated2018-01-26T23:36:28Zpt_BR
dc.subject.nalthesaurusModels
dc.subject.nalthesaurusMolecular dynamics
dc.subject.nalthesaurusHypertension
riaa.ainfo.id9091
riaa.ainfo.lastupdate2018-01-26
dc.contributor.institutionJORGE HERNANDEZ FERNANDEZ, Instituto Butantan; GORAN NESHICH, CNPTIA; ANTONIO CARLOS M. CAMARGO, Instituto Butantan.
Aparece nas coleções:Artigo em periódico indexado (CNPTIA)

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Usingbradykininpotentiatingpeptidestr.pdf1,57 MBAdobe PDFThumbnail
Visualizar/Abrir
Mostrar registro simples do item Visualizar estatísticas

FacebookTwitterDeliciousLinkedInGoogle BookmarksMySpace